Genome sequencing business Ultima Genomics has occur out of stealth and declared $600 million in financing. Launched in 2016 by its Israeli CEO Gilad Almogy, the business has 350 employees including 50 in Israel at growth centers in Rehovot and Hod Hasharon, and remarkably has managed to reduce any leaks of information from its staff, buyers and growth facilities.

The business has now discovered that it has formulated a sequencing machine, which it claims, backed up by research established to be posted in leading scientific periodicals, will allow genome sequencing for $100, in comparison with the $500-600 it costs applying its rival Illumina (Nasdaq: ILMN). In addition, Ultima Genomics claims that its genomic sequencing is more quickly and deeper – in other terms, it presents a lot more information about the genome, more rapidly.

The advantages of these enhancements, which are authorized by means of patents that the enterprise has not nevertheless unveiled, are largely in two directions. Via this technological innovation, the business estimates and hopes, it will be attainable to accomplish genome sequencing even down to single cells, and so diagnose health problems even previously than at present, mostly cancer. In addition, sequencing that is more cost-effective, a lot quicker and richer in information and facts, will permit substantially more rapidly development in tasks that examine the genetics of the genuine morbidity of substantial figures of people today, in order to map the genes included in a variety of conditions.

Resources at Ultima Genomics say that the explanation for the secrecy about the yrs was the desire to attain the position the place the organization could show its products, ahead of producing any announcements. The company also chosen not to stir up its rivals, mainly Illumina.

Ultima Genomics CEO and founder Gilad Almogy is a graduate of the IDF’s Talpiot science and management program. Almogy is currently resident in the US. He was a senior vice president at Used Products just before founding photo voltaic electrical power firm Cogenra Photo voltaic in 2009, which was acquired by SunPower in 2015. In late 2016, Almogy launched Ultima.

Almogy said, “DNA is nature’s storage media and the instruction set for each and every residing organism, but with present systems, we can’t access that data at the scale essential to truly fully grasp sophisticated biology. Our architecture is supposed for radical scaling, and the $100 genome is just the initial example of what it can produce. We are dedicated to continuously travel down the value of genomic info until finally it is routinely made use of in each individual aspect of the healthcare program.”




Connected Posts




aMoon closes $660m Israeli overall health-tech VC fund







Ultima Genomics CSO Doron Lipson included, “Scientists and clinicians continually make tradeoffs concerning the breadth, depth, and frequency of genomic information and facts they obtain. By overcoming the constraints of typical upcoming-era sequencing technologies, scientists can now layout experiments and scientific assays that had been beforehand difficult.”

One of the very first investors in Ultima Genomics was Israeli billionaire and Look at Stage founder Marius Nacht, who is also a graduate of the IDF’s Talpiot application. Nqcht launched the aMoon healthtech and lifestyle science financial commitment fund, initially investing his possess belongings just before getting to be an independent fund, which in current yrs elevated a $750 million development fund. aMoon has also invested in Ultima Genomics.

Other buyers in Ultima Genomics involve D1 Money, Andreessen Horowitz, Standard Atlantic, Khosla Ventures, Lightspeed, Playground Global, and Founders Fund.

Whole disclosure: Marius Nacht is the former lifestyle husband or wife of Anat Agmon, element of the managing shareholders in “Globes.” They are concerned in a private and financial dispute

Released by Globes, Israel business information – en.globes.co.il – on June 2, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.


